Using Absorption Prediction Tools to Optimize Formulation Strategy at the Preclinical Stage

Register Free: https://www.pharmtech.com/pt_w/stage

Event Overview:

Effective prediction tools—used in the preclinical stage of drug development—can help formulators better understand the rate, extent, and limitations of absorption of a novel drug candidate. These tools—along with in-vivo animal studies—also can help evaluate the effect of different of formulations to guide formulation selections.

Register for this webinar to learn about tools and technologies that enable cohesive data generation and analysis to lead to informed formulation decisions in the preclinical stage. Cases studies demonstrating applications for the tools will be shared.

Key Learning Objectives:

• Understand the importance of assessing absorption challenges early
• Review tools and technologies that have demonstrated cost and time savings
• Learn how CDMO/sponsor partnerships can best use developability technologies

Who Should Attend:

• Head of new drug development
• Head of pharmaceutical R&D
• Head of Formulation Development
• Head of CMC
• Formulation scientist
• Drug development scientist

Speakers

Rick Panicucci, Ph.D.
SVP CMC
QED Therapeutics

Prior to joining BridgeBio, Rick Panicucci was global head of chemical and pharmaceutical profiling at Novartis. His responsibilities included all small-molecule therapeutics across the Novartis portfolio. He received a doctorate in chemistry from the University of Toronto and did a post-doctoral fellowship at University of California, Santa Barbara.

Rick Panicucci is currently the senior vice president of CMC at QED Therapeutics, Origin Biosciences, and Calcilytix Therapeutics, all BridgeBio companies. Prior to joining BridgeBio, Rick served as vice president of pharmaceutical development services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick was Global head of chemical and pharmaceutical profiling at Novartis. His responsibilities included all small-molecule therapeutics across the Novartis portfolio. He also led and developed novel drug delivery technologies for small molecules and large molecules. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. He received a doctorate in chemistry from the University of Toronto and did a post-doctoral fellowship at University of California, Santa Barbara.

Liang Mao
Director, Developability and Formulation Research
WuXi STA

Prior to WuXi STA, Liang Mao worked at Novartis for six years on the preformulation team supporting compound developability assessment, physical form screening and selection, and preclinical formulation development. Liang holds a master’s degree in biochemical engineering from Nanjing University of Technology. Liang Mao, currently director at STA WuXi AppTec Shanghai site, joined STA for more than 3 years ago and now manages the developability and formulation research team. Prior to STA, Liang worked at Novartis for six years on the preformulation team supporting compound developability assessment, physical form screening and selection, and preclinical formulation development. He has four years of experience at a research institute and biopharmaceutical company supporting early drug development. He has expertise in drug developability assessment, physical form screening, and bioavailability enhancement technologies. Liang holds a master’s degree in biochemical engineering from Nanjing University of Technology.

Register Free: https://www.pharmtech.com/pt_w/stage